[Yu Jin-hee, Edaily Reporter] While foreign and institutional capital continues to be heavily concentrated in the semiconductor sector of the South Korean stock market, the biotechnology segment successfully held its ground on June 11, buoyed by clear clinical milestones and strong corporate governance. Investor sentiment is rapidly coalescing around enterprises backed by solid earnings momentum and proactive management efforts to restore market trust.

In particular, key growth stocks that demonstrated rigorous data validation and a commitment to responsible management stood out even amidst a broader market downturn. The three standout companies—GI Innovation, Orient Bio, and L&C Bio—all posted double-digit gains relative to the overall market on the day, driving an upward rally for the biotech sector by attracting strong buying pressure.

In-Depth Analysis: GI Innovation Soars on Revolutionary 'GI-101A' Data Validated at a Global Top-Tier Oncology Conference

On the day, GI Innovation (358570) surged 15.40% from the previous trading day on the KOSDAQ market, closing at 13,640 won and topping the list of gainers in the biotech sector. This performance was driven by a combination of a bullish analysis report from a prominent U.S. healthcare investment bank (IB) and strong momentum ahead of an upcoming oral presentation at the world’s largest cancer symposium, triggering a wave of institutional and foreign buy orders.

Recently, U.S. healthcare investment bank Leerink Partners highlighted GI Innovation’s next-generation immuno-oncology candidate, ‘GI-101A’, as a highly promising, market-disrupting program in its 'ASCO 2026' Immuno-Oncology Review Report. The report provided an in-depth analysis suggesting that while global oncology investment trends are currently heavily skewed toward antibody-drug conjugates (ADCs) or VEGF/PD-1 bispecific antibodies, the true paradigm shift moving forward will be driven by the Interleukin-2 (IL-2) bispecific fusion antibody (bs-fusion-Ab) space.

Positioned at the center of this major trend, GI-101A is scheduled to be presented in an oral session detailing its Phase 1/2 clinical trial results at the American Society of Clinical Oncology (ASCO 2026) annual meeting on May 30 (local time).

The presentation will be delivered by Dr. Jae-Lyun Lee, a global key opinion leader (KOL) in urologic oncology, drawing intense attention from global biopharma CEOs and business development (BD) executives. Among numerous abstracts, the selection of an early-stage clinical dataset for an oral presentation session is a significant indicator that the global medical community highly values this core pipeline.

The pre-released abstract data exceeded market expectations. In the effective dose cohort (0.2–0.3 mg/kg) of the monotherapy arm, a monumental milestone was achieved: a complete response (CR) was induced in a patient with refractory bladder cancer who had previously shown no response to conventional immune checkpoint inhibitors.

The patient’s progression-free survival (PFS) was confirmed at 13.9 months—an outstanding figure that is more than double the previously reported PFS data (approximately 6 months) for Padcev, the current standard of care in clinical practice. Furthermore, a partial response (PR) was observed in a patient with immune checkpoint inhibitor-refractory malignant mesothelioma, further demonstrating the candidate’s anti-tumor activity.

The combination therapy arm with the global blockbuster drug Keytruda (pembrolizumab) is equally encouraging. In the clear cell renal cell carcinoma (ccRCC) cohort—which holds the most accumulated data among the 48 solid tumor patients enrolled—the combination yielded an impressive objective response rate (ORR) of 40% and a disease control rate (DCR) of 70%.

Although 70% of the total patient population consisted of individuals who had previously failed immunotherapy, the duration of response lasted up to 16.7+ months. Since the majority of these patients are still undergoing treatment, there is a strong likelihood that the final PFS data will improve even further.

An official from GI Innovation stated, "GI-101A is demonstrating a clear trend where antitumor activity increases in a dose-proportional manner. Even after the abstract submission deadline, overwhelming results exceeding previous data in terms of response durability and ORR continue to accumulate in real time. We look forward to presenting these highly encouraging findings at the ASCO conference."

Orient Bio Rallies on Strong Corporate Governance Initiatives Following Stock Merge and Progress on 3 Major Growth Strategies

Closing at 978 won, a sharp 14.12% increase from the previous day, Orient Bio (002630) saw its stock price rise sharply, driven by an ambitious declaration to upgrade its business structure and momentum surrounding management’s equity expansion. Following the completion of corporate restructuring, including a stock consolidation and the listing of new shares, the company officially announced detailed measures to enhance mid- to long-term corporate value on the morning of June 11, successfully winning the trust of savvy investors.

Orient Bio’s management explicitly stated that the current stock price does not fully reflect the company’s intrinsic asset value and independent future growth potential. Accordingly, they announced that the largest shareholder, related parties, and affiliates are actively exploring various methods to increase their stake within legal limits, including open-market purchases. The market interpreted this move as a strong signal of the major shareholders’ commitment to price stabilization and responsible governance, serving as a powerful catalyst for buying.

The company outlined three core pillars for its future growth trajectory. Specifically, these are: △the advancement of the innovative hair loss treatment candidate ‘OND-1’, △the expansion of the global non-human primate (NHP) core infrastructure business, and △the establishment of an artificial intelligence (AI)-driven next-generation bio platform. As a company that has long maintained a highly competitive edge in the laboratory animal production and preclinical research support markets, Orient Bio plans to seamlessly apply its accumulated bio-infrastructure operational expertise to these new business engines.

OND-1, the centerpiece of the company’s drug development division, is aggressively ramping up its research capabilities and R&D investment with the ultimate goal of clinical entry and commercialization. The laboratory animal segment is also poised for a major step up; with global demand for high-quality primates exploding in tandem with the boom in biopharmaceutical development, Orient Bio intends to proactively reinforce its overseas supply chain to elevate its global market dominance.

In parallel, the company is building a next-generation bio-digital platform that integrates massive preclinical big data with AI algorithms. This strategy aims to maximize overall research efficiency by digitizing the drug candidate screening and preclinical testing processes, ultimately creating a new revenue stream through a "Bio-Business-as-a-Service" model. Through these structural improvements and company-wide operational efficiency upgrades, the company has made a concrete commitment to shareholders to achieve a turnaround and return to profitability by the next fiscal year.

An official from Orient Bio stated, "This is a process of integrating high-value-added areas such as drug discovery and AI bio-platforms onto the solid foundation of our top-tier laboratory animal infrastructure business, which is our core strength. Rather than merely relying on slogans, we will maximize mid- to long-term corporate value through tangible results that satisfy the market, alongside accountable management by our major shareholders."

L&C Bio Surges on Corporate Value Jump, Spurred by Re2O Market Penetration and High-Growth Expectations

L&C Bio, a company specializing in tissue regenerative medicine, closed at 84,000 won, up 12.60% from the previous day, as anticipation surrounding the financial growth of its extracellular matrix (ECM)-based innovative regenerative solution, ‘Re2O,’ combined with positive global academic marketing achievements.

L&C Bio previously demonstrated its robust underlying potential through its Q1 earnings report. The company’s Q1 consolidated revenue surged 70.6% year-over-year to 303 billion won, while operating profit reached 6.0 billion won, marking a successful return to profitability.

This milestone was achieved despite a significant initial fixed-cost burden resulting from the aggressive expansion of production facilities and the hiring of a large number of quality control personnel to meet the surging demand for Re2O. In fact, the company demonstrated both top-line growth and operational efficiency simultaneously, posting an exceptional consolidated operating profit margin of 19.8% and a standalone operating profit margin of 27.2%.

This performance signifies that Re2O has successfully established itself in the premium medical market, positioning itself as the primary growth engine. Immediately following its launch, Re2O saw its adoption rate skyrocket through strong word-of-mouth among dermatologists and plastic surgeons. Moving beyond a trendy aesthetic product, it has played a pivotal role in restructuring L&C Bio’s mid-to-long-term business model toward a high-margin configuration.

Market attention is now focused on the production capacity (CAPA) expansion timeline required to support Re2O’s steep sales growth trajectory. Currently, the company is progressively scaling up its production capabilities from the previous level of 35,000 units per month.

Having successfully established a monthly production capacity of 80,000 units as of May, the company plans to significantly expand its CAPA to 150,000 units per month starting this coming November. As the increased volume hits the market in the second half of the year, the pace of revenue growth is expected to accelerate further. Combined with the company’s existing flagship human tissue implant product, ‘Megaderm’—which continues to serve as a rock-solid cash cow backed by extensive clinical data and deep market trust—L&C Bio has established an ideal portfolio that balances stability with high growth.

The company’s expansion into global markets is also progressing smoothly. L&C Bio announced that it successfully held an exclusive webinar for over 200 local medical professionals in Myanmar on June 11, focusing on Re2O, the world’s first skin booster utilizing human acellular dermal matrix (hADM).

Held under the theme “The ECM Revolution Begins,” the seminar explained Re2O’s clinical mechanism for fundamentally reversing skin aging by restoring the skin’s natural ECM environment, along with precise injection techniques using the dedicated injector “i-ject B.” The presentation received enthusiastic praise from the Southeast Asian physicians in attendance.

An official from L&C Bio stated, “Re2O is just at the beginning of a massive global growth phase. By strategically upgrading our integrated platform strategy, we will establish an unrivaled global regenerative medicine ecosystem that encompasses everything from diagnosis and treatment to full tissue reconstruction.”